Cargando…

Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer

OBJECTIVES: To evaluate PSA levels and kinetic cutoffs to predict positive bone scans for men with non-metastatic castrate resistant prostate cancer (CRPC) from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. METHODS: Retrospective analysis of 531 bone scans of 312 clinically CRPC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moreira, Daniel M., Howard, Lauren E., Sourbeer, Katie N., Amarasekara, Hiruni S., Chow, Lydia C., Cockrell, Dillon C., Hanyok, Brian T., Pratson, Connor L., Aronson, William J., Kane, Christopher J., Terris, Martha K., Amling, Christopher L., Cooperberg, Matthew R., Liede, Alexander, Freedland, Stephen J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640947/ https://www.ncbi.nlm.nih.gov/pubmed/26171882 http://dx.doi.org/10.1038/pcan.2015.25

Ejemplares similares

Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH
por: Hanyok, Brian T., et al.
Publicado: (2019)

Time Trends in Use of Radical Prostatectomy by Tumor Risk and Life Expectancy in a National Veterans Affairs Cohort
por: Vaculik, Kristina, et al.
Publicado: (2021)

A modeling study to estimate prostate cancer‐specific mortality on active surveillance for men with favorable intermediate‐risk prostate cancer: Results from the SEARCH cohort
por: Kuhlmann, Paige K., et al.
Publicado: (2023)

Validity of the National Death Index to Ascertain the Date and Cause of Death in Men Having Undergone Prostatectomy for Prostate Cancer
por: Moghanaki, Drew, et al.
Publicado: (2019)

Red Blood Cell Distribution Width Is Associated with All-cause Mortality but Not Adverse Cancer-specific Outcomes in Men with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy: Findings Based on a Multicenter Shared Equal Access Regional Cancer Hospital Registry
por: Orabi, Hazem, et al.
Publicado: (2022)

Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database
por: Vidal, A C, et al.
Publicado: (2017)

Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy
por: Kelkar, Sonia, et al.
Publicado: (2021)

Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database
por: Allott, Emma H., et al.
Publicado: (2013)

The Influence of Hepatic Function on Prostate Cancer Outcomes Following Radical Prostatectomy
por: Bañez, Lionel L., et al.
Publicado: (2010)

Bone scan positivity in non-metastatic, castrate-resistant prostate cancer: external validation study
por: Johnston, Ashley W., et al.
Publicado: (2020)

Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
por: Freedland, Stephen J., et al.
Publicado: (2023)

Nutrition, dietary interventions and prostate cancer: the latest evidence
por: Lin, Pao-Hwa, et al.
Publicado: (2015)

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
por: George, Daniel J., et al.
Publicado: (2021)

Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration
por: Freedland, Stephen J., et al.
Publicado: (2021)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
por: Nickols, Nicholas G., et al.
Publicado: (2019)

Castration
por: Pugh, T. J.
Publicado: (1897)

Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States
por: Ryan, Charles J., et al.
Publicado: (2021)

Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD
por: de Wit, Ronald, et al.
Publicado: (2022)

The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
por: Pan, Jian, et al.
Publicado: (2022)

Hybrid input-output analysis of embodied energy security
por: Shepard, Jun U., et al.
Publicado: (2020)

Reminiscences of Castration
por: Treacy, M. J.
Publicado: (1895)

Effect of Dietary Omega-3 Fatty Acids on Castrate Resistant Prostate Cancer and Tumor Associated Macrophages
por: Liang, Pei, et al.
Publicado: (2019)

Development of a preliminary nomogram to predict progression of bone scan for castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2015)

Current perspectives on bone metastases in castrate-resistant prostate cancer
por: Logothetis, Christopher, et al.
Publicado: (2018)

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection
por: LeVee, Alexis, et al.
Publicado: (2021)

Castration of Cryptorchids (Ridglings)
por: Andre, V. J.
Publicado: (1900)

Castration of Cryptorchids (Ridglings)
por: Butterfield, J. F.
Publicado: (1899)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer
por: Higano, Celestia S., et al.
Publicado: (2019)

SUN-238 Estrogen Modulates Expression Levels of Gonadotropin-Releasing Hormone Receptor (GNRHR) in Immortalized Kisspeptin Neurons in Vitro
por: Rayzmann, Noa, et al.
Publicado: (2020)

Transdermal estradiol in castrate and chemotherapy resistant prostate cancer
por: Stein, Mark, et al.
Publicado: (2012)

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer
por: Miller, Katie Joanna, et al.
Publicado: (2023)

Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting
por: Freedland, Stephen J., et al.
Publicado: (2022)

Secondary Immune Thrombocytopenia in Metastatic Renal Cell Carcinoma: A Case Report and Discussion of the Literature
por: Cockrell, Dillon C., et al.
Publicado: (2020)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Uemura, Koichi, et al.
Publicado: (2018)

Castration failure in prostate carcinoma due to a functioning adrenocortical carcinoma
por: Navani, Vishal, et al.
Publicado: (2021)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide
por: Anand, Aseem, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cq498e39mrn2f90t8apfo0st0c